| Japanese |
|---|
| Title | 99mTc-tetrofosminを用いた心筋SPECTの臨床応用 - 全国多施設による共同研究 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 西村恒彦*, 延吉正清** |
|---|
| Authors(kana) | |
|---|
| Organization | *大阪大学医学部トレーサ情報解析, **小倉記念病院循環器科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 32 |
|---|
| Number | 9 |
|---|
| Page | 1007-1021 |
|---|
| Year/Month | 1995/9 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」全国44施設にて虚血性心疾患212症例を対象として, 急性期再灌流療法, 待期的PTCA, 心筋viabilityの評価を99mTc-tetrofosmin心筋SPECTを用いて施行, 以下の結論を得た. 1)99mTc-tetrofosmin安静時心筋SPECTにより, 急性期再灌流療法の評価が可能であった. 急性期から亜急性期にかけて約25%, 亜急性期から慢性期にかけて約10%の心筋salvageが認められた. 慢性期の左室造影による局所壁運動異常は亜急性期, 慢性期における局所心筋血流異常と良好な相関を示した. また亜急性期における99mTc-tetrofosmin心筋集積度は, 局所壁運動の改善に関する有用な指標となりうることが示唆された. 2)99mTc-tetrofosmin負荷/安静時心筋SPECTにより, 待期的PTCAの適応決定および治療効果の判定が行えた. 3)99mTc-tetrofosmin負荷/安静時心筋SPECTは201Tl負荷/再分布法に比し良好に, また, 201Tl負荷/再静注法と同等度に心筋viabilityの評価が行えた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc-tetrofosmin, Acute thrombolysis, PTCA, Myocardial viability, Multicenter trial. |
|---|
| English |
|---|
| Title | Clinical Application of 99mTc-Tetrofosmin Myocardial SPECT - A Multicenter Trial - |
|---|
| Subtitle | |
|---|
| Authors | Tsunehiko NISHIMURA*, Masakiyo NOBUYOSHI** |
|---|
| Authors(kana) | |
|---|
| Organization | *Tracer Kinetics, Osaka University, Medical School, **Cardiac Division, Kokura Memorial Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 32 |
|---|
| Number | 9 |
|---|
| Page | 1007-1021 |
|---|
| Year/Month | 1995/9 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | We performed a multicenter trial of 99mTc-tetrofosmin myocardial SPECT for the assessment of acute thrombolysis, pre and post elective PTCA and myocardial viability in comparison with 201Tl myocardial SPECT. The participants consisted of 212 patients at 44 institutions and the study lasted for 10 months. In assessing acute thrombolysis, the perfusion defect from the acute to subacute phase was reduced by 25% and that from the subacute to chronic phase by 10%. The mean perfusion defect score at subacute and chronic phase was correlated well with regional wall motion. The mean defect score during the subacute phase could predict future wall motion abnormalities. In assessing pre and post PTCA, 99mTc-tetrofosmin stress/rest myocardial SPECT could identify the changes of perfusion as in the case with successful PTCA and/or restenosis. In assessing the myocardial viability, 99mTc-tetrofosmin rest myocardial SPECT was superior to 201Tl redistribution, and equal to 201Tl reinjection method. In summary, we concluded that 99mTc-tetrofosmin is a powerful tool, with which to diagnose and manage patients with coronary artery diseases. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc-tetrofosmin, Acute thrombolysis, PTCA, Myocardial viability, Multicenter trial. |
|---|